Tredaptive: treating raised LDL-cholesterol and beyond
Significant reductions in cardiovascular risk have been achieved over the past 20 years using statins to reduce levels of low-density lipoprotein (LDL) cholesterol and total cholesterol. However, there is growing evidence that managing only this lipid fraction may not optimally reduce patients’ CVD risk, particularly in those with type 2 diabetes or the metabolic syndrome. Low levels of high-density lipoprotein (HDL) cholesterol and raised triglycerides are important, but often overlooked, elements of the dyslipidaemic profile that commonly occur in these patients. Tredaptive offers the potential for reaching optimal nicotinic acid dosage and thereby a convenient option for achieving significant improvements on all three fronts of lipid modification – LDL cholesterol, HDL cholesterol and triglycerides, primarily because of significant reduction in the most troublesome sideeffect of nicotinic acid, facial flushing.